Role of RANKL inhibition in osteoporosis

Arthritis Research and Therapy

Volumn 9, Issue SUPPL.1, 2007, Pages

  McClung, Michael ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; ESTROGEN; GLUCOCORTICOID; IMMUNOGLOBULIN FC FRAGMENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OSTEOPROTEGERIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT OSTEOPROTEGERIN; RISEDRONIC ACID; VITAMIN D;

ABSENCE OF SIDE EFFECTS; APPLICATION SITE REACTION; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FRACTURE; HIP FRACTURE; HUMAN; HYPOCALCEMIA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; OSTEOPOROSIS; RANK LIGAND;

EID: 34548413629     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2167     Document Type: Review

References (50)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy JAMA 2001, 285:785-795. 10.1001/jama.285.6.785 11176917
2. Johnell O Kanis JA Oden A Sernbo I Redlund-Johnell I Petterson C De Laet C Jonsson B Mortality after osteoporotic fractures Osteoporos Int 2004, 15:38-42. 10.1007/s00198-003-1490-4 14593451
3. US Department of Health and Human Services Bone Health and Osteoporosis: A Report of the Surgeon General Washington, DC: Public Health Service, Office of the Surgeon General 2004
4. Silverman SL The clinical consequences of vertebral compression fracture Bone 1992, (Suppl 2):S21-S31.
5. Johnell O Kanis JA Oden A Sernbo I Redlund-Johnell I Petterson C De Laet C Jonsson B Fracture risk following an osteoporotic fracture Osteoporos Int 2004, 15:175-179. 10.1007/s00198-003-1514-0 14691617
6. Gullberg B Johnell O Kanis JA World-wide projections for hip fracture Osteoporos Int 1997, 7:407-413. 10.1007/PL00004148 9425497
7. Heaney RP Abrams S Dawson-Hughes B Looker A Marcus R Matkovic V Weaver C Peak bone mass Osteoporos Int 2000, 11:985-1009. 10.1007/s001980070020 11256898
8. Raisz LG Pathogenesis of osteoporosis: Concepts, conflicts, and prospects J Clin Invest 2005, 115:3318-3325. 1297264 16322775 10.1172/ JCI27071
9. Robbins JA Schott AM Garnero P Delmas PD Hans D Meunier PJ Risk factors for hip fracture in women with high BMD: EPIDOS study Osteoporos Int 2005, 16:149-154. 10.1007/s00198-004-1661-y 15185066
10. Dufresne TE Chmielewski PA Manhart MD Johnson TD Borah B Risedronate preserves bone architecture in early post-menopausal women in 1 year as measured by three-dimensional microcomputed tomography Calcif Tissue Int 2003, 73:423-432. 10.1007/s00223-002-2104-4 12964065
11. Lips P Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications Endocr Rev 2001, 22:477-501. 10.1210/er.22.4.477 11493580
12. Marshall D Johnell O Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 1996, 312:1254-1259. 8634613
13. Kanis JA Diagnosis of osteoporosis and assessment of fracture risk Lancet 2002, 359:1929-1936. 10.1016/S0140-6736(02)08761-5 12057569
14. Bischoff-Ferrari HA Willett WC Wong JB Giovannucci E Diet-rich T Dawson-Hughes B Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials JAMA 2005, 293:2257-2264. 10.1001/jama.293.18.2257 15886381
15. Kannus P Parkkari J Niemi S Pasanen M Palvanen M Järvinen M Vuori I Prevention of hip fracture in elderly people with use of a hip protector N Engl J Med 2000, 343:1506-1513. 10.1056/NEJM200011233432101 11087879
16. The Writing Group for the PEPI Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial JAMA 1996, 276:1389-1396. 10.1001/ jama.276.17.1389 8892713
17. Delmas PD Bjarnason NH Mitlak BH Ravoux AC Shah AS Huster WJ Draper M Christiansen C Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 1997, 337:1641-1647. 10.1056/NEJM199712043372301 9385122
18. McClung MR Wasnich RD Hosking DJ Christiansen C Ravn P Wu M Mantz AM Yates J Ross PD Santora AC Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort J Clin Endocrinol Metab 2004, 89:4879-4885. 10.1210/jc.2003-031672 15472179
19. Delmas PD Treatment of postmenopausal osteoporosis Lancet 2002, 359:2018-2026. 10.1016/S0140-6736(02)08827-X 12076571
20. Black DM Cummings SR Karpf DB Cauley JA Thompson DE Nevitt MC Bauer DC Genant HK Haskell WL Marcus R Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 1996, 348:1535-1541. 10.1016/ S0140-6736(96)07088-2 8950879
21. Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 1999, 282:637-645. 10.1001/jama.282.7.637 10517716
22. Harris ST Watts NB Genant HK McKeever CD Hangartner T Keller M Chesnut CH III Brown J Eriksen EF Hoseyni MS Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 1999, 282:1344-1352. 10.1001/ jama.282.14.1344 10527181
23. Neer RM Arnaud CD Zanchetta JR Prince R Gaich GA Reginster JY Hodsman AB Eriksen EF Ish-Shalom S Genant HK Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 2001, 344:1434-1441. 10.1056/ NEJM200105103441904 11346808
24. McClung MR Geusens P Miller PD Zippel H Bensen WG Roux C Adami S Fogelman I Diamond T Eastell R Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 2001, 344:333-340. 10.1056/ NEJM200102013440503 11172164
25. Black DM Greenspan SL Ensrud KE Palermo L McGowan JA Lang TF Garnero P Bouxsein ML Bilezikian JP Rosen CJ The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 2003, 349:1207-1215. 10.1056/NEJMoa031975 14500804
26. Finkelstein JS Hayes A Hunzelman JL Wyland JJ Lee H Neer RM The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 2003, 349:1216-1226. 10.1056/NEJMoa035725 14500805
27. Recker RR Gallagher R MacCosbe PE Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 2005, 80:856-861. 16007889
28. Caro JJ Ishak KJ Huybrechts KF Raggio G Naujoks C The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 2004, 15:1003-1008. 10.1007/s00198-004-1652-z 15167989
29. Hofbauer LC Khosla S Dunstan CR Lacey DL Boyle WJ Riggs BL The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J Bone Miner Res 2000, 15:2-12. 10.1359/ jbmr.2000.15.1.2 10646108
30. Bucay N Sarosi I Dunstan CR Morony S Tarpley J Capparelli C Scully S Tan HL Xu W Lacey DL Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Gene Dev 1998, 12:1260-1268. 316769 9573043
31. Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett L Boone T Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3 9108485
32. Hofbauer LC Khosla S Dunstan CR Lacey DL Spelsberg TC Riggs BL Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Endocrinology 1999, 140:4367-4370. 10.1210/ en.140.9.4367 10465311
33. Lochlin RM Khosla S Turner RT Riggs BL Mediators of the bisphasic responses of bone to intermittent and continuously administered parathyroid hormone J Cell Biochem 2003, 89:180-190. 10.1002/jcb.10490 12682918
34. Hofbauer LC Gori F Riggs BL Lacey DL Dunstan CR Spelsberg TC Khosla S Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells Endocrinology 1999, 140:4382-4389. 10.1210/en.140.10.4382 10499489
35. Kong YY Feige U Sarosi I Bolon B Tafuri A Morony Capparelli C Li J Elliott R McCabe S Wong T Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through Osteoprotegerin ligand Nature 1999, 402:304-309. 10.1038/46303 10580503
36. Takayanagi H Iizuka H Juji T Nakagawa T Yamamoto A Miyazaki T Koshihara Y Oda H Nakamura K Tanaka S Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis Arthritis Rheum 2000, 43:259-269. 10.1002/ 1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W 10693864
37. Collin-Osdoby P Rothe L Anderson F Nelson M Maloney W Osdoby P Receptor activator of NF-kappa B and osteoprote-gerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis J Biol Chem 2001, 276:20659-20672. 10.1074/jbc.M010153200 11274143
38. Min H Morony S Sarosi I Dunstan CR Capparelli C Scully S Van G Kaufman S Kostenuik PJ Lacey DL Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med 2000, 192:463-474. 10.1084/jem.192.4.463 10952716
39. Bolon B Carter C Daris M Morony S Capparelli C Hsieh A Mao M Kostenuik P Dunstan CR Lacey DL Sheng JZ Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis Mol Ther 2001, 3:197-205. 10.1006/mthe.2001.0245 11237676
40. Capparelli C Morony S Warmington K Adamu S Lacey D Dunstan CR Stouch B Martin S Kostenuik PJ Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats J Bone Miner Res 2003, 18:852-858. 10.1359/jbmr.2003.18.5.852 12733724
41. Shimizu-Ishiura M Kawana F Sasaki T Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function J Electron Microsc 2002, 51:315-325. 10.1093/jmicro/51.5.315
42. Bateman TA Dunstan CR Ferguson VL Lacey DL Ayers RA Simske SJ Osteoprotegerin mitigates tail suspension-induced osteopenia Bone 2000, 26:443-449. 10.1016/S8756-3282(00)00256-8 10773583
43. Kostenuik PJ Ominsky MS Cramner P Atkinson J The RANKL antagonist OPG-Fc causes significant increases in cortical bone thickness, density, and bone strength index in adult female cynomologus monkeys Osteoporos Int 2005, (Suppl 3):S68.
44. Atkinson J Cranmer P Saunders T Niehaus M Smith SY Varela A Ominsky MS Cosenza ME Kostenuik PJ AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys J Bone Miner Res 2005, 20:S29.
45. Kostenuik PJ Capparelli C Morony S Adamu S Shimamoto G Shen V Lacey DL Dunstan CR OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Endocrinology 2001, 142:4295-4304. 10.1210/en.142.10.4295 11564687
46. Valenta A Roschger P Fratzl-Zelman N Kostenuik PJ Dunstan CR Fratzl P Klaushofer K Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats Bone 2005, 37:87-95. 10.1016/j.bone.2005.03.013 15869920
47. Bekker PJ Holloway D Nakanishi A Arrighi M Leese PT Dunstan CR The effect of a single dose of osteoprotegerin in post-menopausal women J Bone Miner Res 2001, 16:348-360. 10.1359/jbmr.2001.16.2.348 11204435
48. Bekker PJ Holloway DL Rasmussen AS Murphy R Martin SW Leese PT Holmes GB Dunstan CR DePaoli AM A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 2004, 19:1059-1066. 10.1359/JBMR.040305 15176987
49. McClung MR Lewiecki EM Cohen SB Bolognese MA Woodson GC Moffett AH Peacock M Miller PD Lederman SN Chesnut CH Denosumab in postmenopausal women with low bone mineral density N Engl J Med 2006, 354:821-831. 10.1056/NEJMoa044459 16495394
50. Lewiecki EM Miller PD McClung MR Cohen SB Liu Y Wang A Fitzpatrick LA Denosumab (AMG 162) inhibition of RANK ligand increases bone mineral density in postmenopausal osteoporosis women after two years of treatment Osteoporos Int 2006, (Suppl 2):S4.